In the modern medical era, more diverse and effective treatment options have translated to increased life expectancy. With this increased life span comes increased age-associated disease and the dire need to understand underlying causes so that therapies can be designed to mitigate the burden to health and the economy. Aging exacts a seemingly inevitable multisystem deterioration of function that acts as a risk factor for a variety of age-related disorders, including those that devastate organs of limited regenerative potential, such as the brain. Rather than studying the brain and mechanisms that govern its aging in isolation from other organ systems, an emerging approach is to understand the relatively unappreciated communication that exists between the brain and systemic environment. Revisiting classical methods of experimental physiology in animal models has uncovered surprising regenerative activity in young blood with translational implications for the aging liver, muscle, brain, and other organs. Soluble factors present in young or aged blood are sufficient to improve or impair cognitive function, respectively, suggesting an aging continuum of brain-relevant systemic factors. The age-associated plasma chemokine CCL11 has been shown to impair young brain function while GDF11 has been reported to increase the generation of neurons in aged mice. However, the identities of specific factors mediating memory-enhancing effects of young blood and their mechanisms of action are enigmatic. Here we review brain rejuvenation studies in the broader context of systemic rejuvenation research. We discuss putative mechanisms for blood-borne brain rejuvenation and suggest promising avenues for future research and development of therapies.

Aging as a Multisystem Problem

Aging drives a progressive decline in cognitive function that renders the brain susceptible to devastating neurological disorders, including Alzheimer disease. Aging is the strongest risk factor for the development of Alzheimer disease, a neurodegenerative disease with no effective treatment that culminates in synaptic dysfunction, neuronal death, and impaired memory and other cognitive functions. By 2050, the number of elderly individuals older than 80 years is projected to triple globally, many of whom will have cognitive impairment, Alzheimer disease, or 1 of several other neurodegenerative diseases for which age increases risk. As the number of aged individuals increases dramatically in the next several decades, widespread social and economic consequences of these and other aging disorders will be felt on an unprecedented scale. One strategy to meet this growing public health threat is to elucidate the mechanisms that underlie cognitive decline to inform therapeutic strategies aimed at ameliorating age-associated disease. As the brain ages, various cell types exhibit hallmark changes, including increased astrogliosis and microgliosis, alterations in the blood-brain barrier, decreased generation of new neurons in specialized areas, and decreased synaptic function, all of which may contribute to impaired cognitive function. The hippocampus in the temporal medial lobe is a region particularly sensitive to the ravages of aging. Cellular changes in this structure manifest as striking impairments in cognitive tasks ascribed to normal hippocampal function, including spatial and episodic learning and memory function. The brain is not unique in its predisposition to age-associated functional decline. Muscle, liver, pancreas, heart, and other organ systems also exhibit declines in function with age, leading to conditions associated with frailty and loss of independence, including sarcopenia, age-associated diabetes mellitus, and cardiac hypertrophy or failure. While many cell-autonomous and tissue-intrinsic mediators of aging have been proposed, recent data support the emerging concept that there is much to learn from potential overlap in the aging process across diverse tissue types. Indeed, a key hallmark shared among age-sensitive organs is a dramatic decline in regenerative potential in specific cell populations. A seminal study published 1 decade ago discovered that the loss of proliferative capacity for aged satellite cells and hepatocytes is not immutable; the exposure of aged tissue to young blood restores latent regenerative capacity, which rejuvenates the muscle and liver. Given the close contact made between the vasculature and a vulnerable brain region, such as the hippocampus, it was hypothesized that the systemic environment could influence or drive how the brain ages. We and others provided evidence that age-related changes in the blood regulate brain function, raising the possibility that central nervous system (CNS) function can be shaped throughout aging by the combined influence of peripheral organ systems via circulatory factors or changes at the interface of communication between these compartments (Figure 1).
Conboy and colleagues\(^2\) tested whether young blood reverses the age-related decline in proliferating hepatocytes in the liver, a separate regenerative peripheral organ. Hepatocytes from aged parabionts of heterochronic pairs indeed exhibit youthful proliferation and a reversal of age-related CEBP-\(\alpha\)-Brm, a complex that accumulates with liver aging. Given that loss of cardiac function and associated failure can be a feature of aging, Loffredo and colleagues\(^6\) used heterochronic parabiosis to show that sharing young blood reduces cardiac hypertrophy. In addition to reducing heart weight in aged mice, young blood exposure markedly decreases the size of ventricular myocytes. While the molecular hypertrophic markers atrial natriuretic peptide and brain natriuretic peptide are not normalized to youthful levels in cardiomyocytes, alterations in expression may indicate a remodeling process caused by the exposure to young blood. Treating aged mice daily for 1 month with GDF11, a protein elevated in the plasma of aged heterochronic parabionts, leads to a reduction in heart weight, a modest but significant reduction in the size of cardiomyocytes, and a corresponding normalization of molecular markers of cardiac hypertrophy. Salpeter and colleagues\(^{11}\) joined 1.5- and 8-month-old mice using heterochronic parabiosis to examine whether young blood could influence the age-related decline in pancreatic \(\beta\)-cell proliferation. After only 2 to 3 weeks of sharing blood, pancreatic \(\beta\) cells from aged mice of the heterochronic pairs displayed higher levels of replication, an effect that is mimicked by transplanting islets from aged mice into young mice. Another study assessed whether age-related systemic changes influenced hair follicle stem cell function.\(^{12}\) While sharing young blood modestly increases the colony-forming efficiency of hair follicle stem cells in skin isolated from aged parabionts, further in vivo experiments argue that the age-related decline in hair follicle stem cells is determined to a greater extent by cell- and tissue-intrinsic factors. The regenerative capacity of aged bone is improved by exposure to young blood.\(^{13}\) Following tibial fractures in the aged mice of heterochronic pairs, bone healing improves compared with that normally observed in aged mice, likely through the modulation of \(\beta\)-catenin signaling.

Following the finding that young blood rejuvenates stem cell activity in muscle,\(^2\) several groups reported that the effects of young blood could extend beyond peripheral organs to mediate rejuvenation in the CNS.\(^{3,5,6}\) Within the dentate gyrus (DG) subgranular zone of the hippocampus, the cellular niche in which the generation of new neurons occurs is closely associated with blood vessels and, thus, systemic factors. Together with the Rando laboratory, Villeda and colleagues\(^4\) used heterochronic parabiosis to examine the influence of the systemic environment on this neurogenic niche. The exposure of aged mice to young blood substantially increases the number of proliferating progenitors and newborn neurons in the DG of aged heterochronic parabionts. Aged blood appears to have opposing effects on DG neurogenesis, which are reminiscent of the inhibitory properties of aged blood on muscle.\(^7\) Plasma protein profiling revealed age-dependent increases in CCL11 and similar elevations in aged human plasma and cerebrospinal fluid. When provided to young mice systemically, CCL11 is sufficient to impair neurogenesis and memory performance. A subsequent study ex-
panded the rejuvenating effects of young blood to that of synaptic plasticity at cellular, transcriptional, and circuit levels. Exposure of aged heterochronic parabionts to young blood strengthens DG synapses and upregulates hippocampal plasticity genes, including immediate early genes linked to learning and memory.1 In a parallel study, the effect of young blood on neurogenesis was examined in a separate neurogenic niche, namely, the subventricular zone.5 The proliferation of neural stem and progenitor cells within this niche is rescued in aged mice exposed to young blood, with corresponding improvements in olfactory behavior. Sharing young blood rescues age-related blood vessel volume loss in the brain and improves cerebral blood flow; the plasma factor GDF11 partially restores vessel loss as well as the proliferative progenitor cell population in the subventricular zone. Young blood–mediated rejuvenation has also been observed in the context of injury.14 Following focal demyelination of the aged spinal cord, young blood exposure restores levels of remyelinating oligodendrocytes to youthful levels and dramatically improves remyelination at the lesion site. Together, these studies demonstrate that young blood restores regenerative activity not only in peripheral organs but also within the CNS, a site conventionally thought to be primarily regulated by intrinsic factors throughout aging (Figure 1).

### Potential Mechanisms and Clinical Applications of Young Blood

The rejuvenating properties of young blood in different organs may represent reactivation of distinct molecular pathways or shared mechanisms that drive aging via the systemic environment. Owing to the isolation of the CNS from the periphery by the blood-brain barrier, blood-mediated rejuvenation may be a reflection of the combined rejuvenation of multiple organs and the transfer of youthful factors into relevant neural niches. Networks of capillaries penetrating memory-relevant niches within the brain may provide an opportunity for the direct exchange of rejuvenating factors, especially in the context of aging or injury when the barriers between the CNS and blood are perturbed (Figure 2).5,14 Recent data raise the possibility that endothelial cells but not pericytes are activated by young blood,5 indirectly affecting the neurovascular unit to ultimately improve neural function. Yet another mechanism may involve surveillance mediated by immune cells acting at the interface of the blood–cerebrospinal fluid barrier, which is supported by the observation that sharing aged blood alters the expression of genes involved in leukocyte entry from the choroid plexus epithelium to cerebrospinal fluid. Whether by direct or indirect signaling, factors in young blood mediate cellular changes in the CNS in ways that are not yet clear. Although young blood influences the activity of oligodendrocytes in the injured spinal cord,14 it is unknown whether these cells are affected in niches within the brain relevant for cognition or to what extent other glia, including astrocytes and microglia, are altered as a result of young blood exposure. A key goal is to understand which cells are affected and whether specific cell types transduce rejuvenating effects to neurons to mediate enhanced plasticity. Young blood activates neural progenitor proliferation, translating to a greater number of mature neurons in specialized brain areas.5,3 While these effects are robust, levels of neurogenesis in the aged rodent brain are markedly lower than in the young brain even after

---

**Figure 2. Young Blood Rejuvenates Various Cell Types in the Central Nervous System (CNS)**

Exposure to young blood stimulates plasticity in the aged CNS (bold), particularly in adult neurogenic processes, oligodendrocyte activity (lesioned spinal cord), synaptic plasticity, and vascularization. How youthful blood-borne factors access the aged CNS is still unclear as is the response of many other cell types that suffer functional decline with age (italics).
rejuvenation, motivating the need to evaluate the contribution to cognitive benefits. However, there is likely much more neurogenesis in the adult human brain than previously appreciated, raising the possibility that restoration of neurogenesis in the human brain could have functionally meaningful benefits. Moreover, computational modeling has suggested that even a small number of newborn neurons can integrate into networks to yield significant functional consequences. Furthermore, while neurogenesis is clearly affected by young blood exposure, it is unclear at what developmental stages these effects are mediated and which molecular pathways are involved.

In addition to enhancing neurogenesis and synaptic plasticity, young blood has been found to improve olfactory memory and other higher-order cognitive functions. Blood plasma, in particular, when administered in mice intravenously as many as 8 times across several weeks, improves hippocampal-memory learning and memory. The key mediators of enhanced plasticity and cognitive function may be proteinaceous based on evidence that heat denaturation ablates positive effects conferred by young plasma. Indeed, the identification of 1 or several factors enriched in young blood that can improve learning and memory function is a key research goal. The advantage of using the soluble component of young blood is that it represents a facile approach to probe many unanswered questions of both a fundamental and translational nature, including interrogation of the effects of young blood at molecular, cellular, circuit, and network levels of analysis.

The demonstration that young or aged plasma improves or impairs brain function, respectively, has many therapeutic implications. With no current treatment for debilitating diseases like Alzheimer disease and given the relative safety of blood plasma products, an appealing approach may be to supply older patients with young plasma to repair damage wrought by the disease on synaptic integrity and function. Both the AMBAR (Alzheimer’s Management by Albumin Replacement) and PLASMA (Plasma for Alzheimer Sympotm Amelioration) trials have been initiated to examine symptom improvements in patients with mild to moderate Alzheimer disease following the removal or addition of blood factors that impair or improve brain function, respectively (NCT01561053 and NCT02256306 at clinicaltrials.gov). Given the likelihood that growth-promoting molecules are abundant in young plasma, it will be important to assess safety to limit the potential for cancer. The promise of treating degenerative disorders of the brain by restoring the peripheral expression of proteins normally produced by the young body is particularly appealing. Restoring the peripheral expression of a rejuvenating factor in a tissue-specific manner may improve brain function while limiting unexpected adverse effects associated with systemic supplementation. Other systemic strategies may also hold great promise for the treatment of aging conditions, including the design of small molecules or antibodies that target age-related elevations in proteins that impair plasticity and cognition, including CCL11. In summary, the possibility that 1 or many proteins in young human blood can rejuvenate a diversity of organs is a tantalizing one that should spur further research, informing both our understanding of the basic biology of aging as well as the development of novel therapies that target diseases of aging.

ARTICLE INFORMATION
Accepted for Publication: June 2, 2015.
Published Online: August 3, 2015.

Conflict of Interest Disclosures: Dr Wyss-Coray is a cofounder of Alkahest Inc. Drs Wyss-Coray and Castellano are listed as inventors on a US patent application related to young plasma filed by Stanford University. No other disclosures were reported.

Funding/Support: This work was funded by a Jane Coffin Childs postdoctoral fellowship sponsored by the Simons Foundation (Castellano), US Department of Veterans Affairs (Wyss-Coray), grant AG045034 from the National Institute on Aging (Wyss-Coray), and grant NS083508 from the National Institute on Neurological Disorders and Stroke (Kirby).

Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

REFERENCES